|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TENT2 |
Gene summary for TENT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TENT2 | Gene ID | 167153 |
| Gene name | terminal nucleotidyltransferase 2 | |
| Gene Alias | APD4 | |
| Cytomap | 5q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0000956 | UniProtAcc | Q6PIY7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 167153 | TENT2 | CCI_2 | Human | Cervix | CC | 2.09e-12 | 1.41e+00 | 0.5249 |
| 167153 | TENT2 | CCI_3 | Human | Cervix | CC | 6.54e-10 | 7.69e-01 | 0.516 |
| 167153 | TENT2 | Tumor | Human | Cervix | CC | 4.20e-08 | -2.07e-01 | 0.1241 |
| 167153 | TENT2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.93e-16 | -5.94e-01 | 0.0155 |
| 167153 | TENT2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.55e-04 | -5.18e-01 | -0.1808 |
| 167153 | TENT2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.98e-05 | -5.62e-01 | -0.1207 |
| 167153 | TENT2 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.57e-04 | -5.23e-01 | -0.1526 |
| 167153 | TENT2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.00e-14 | -5.00e-01 | -0.1464 |
| 167153 | TENT2 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.08e-17 | -5.52e-01 | 0.096 |
| 167153 | TENT2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 4.50e-02 | -7.51e-01 | 0.0446 |
| 167153 | TENT2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.65e-10 | -5.08e-01 | 0.0674 |
| 167153 | TENT2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.13e-06 | -4.84e-01 | 0.0588 |
| 167153 | TENT2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.13e-53 | -8.82e-01 | 0.294 |
| 167153 | TENT2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.20e-19 | -8.82e-01 | 0.281 |
| 167153 | TENT2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.08e-52 | -8.82e-01 | 0.3859 |
| 167153 | TENT2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.59e-15 | -8.82e-01 | 0.2585 |
| 167153 | TENT2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.23e-54 | -8.82e-01 | 0.3005 |
| 167153 | TENT2 | A001-C-207 | Human | Colorectum | FAP | 1.63e-04 | -3.30e-01 | 0.1278 |
| 167153 | TENT2 | A015-C-203 | Human | Colorectum | FAP | 2.61e-33 | -4.95e-01 | -0.1294 |
| 167153 | TENT2 | A015-C-204 | Human | Colorectum | FAP | 1.00e-08 | -4.10e-01 | -0.0228 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0002244 | Colorectum | MSS | hematopoietic progenitor cell differentiation | 32/3467 | 114/18723 | 8.07e-03 | 4.91e-02 | 32 |
| GO:00098954 | Colorectum | FAP | negative regulation of catabolic process | 91/2622 | 320/18723 | 9.66e-12 | 4.96e-09 | 91 |
| GO:00313304 | Colorectum | FAP | negative regulation of cellular catabolic process | 77/2622 | 262/18723 | 6.79e-11 | 2.31e-08 | 77 |
| GO:00064024 | Colorectum | FAP | mRNA catabolic process | 68/2622 | 232/18723 | 9.87e-10 | 2.16e-07 | 68 |
| GO:00064014 | Colorectum | FAP | RNA catabolic process | 77/2622 | 278/18723 | 1.42e-09 | 2.77e-07 | 77 |
| GO:00434874 | Colorectum | FAP | regulation of RNA stability | 53/2622 | 170/18723 | 6.61e-09 | 1.00e-06 | 53 |
| GO:00442704 | Colorectum | FAP | cellular nitrogen compound catabolic process | 101/2622 | 451/18723 | 7.42e-07 | 3.44e-05 | 101 |
| GO:00346554 | Colorectum | FAP | nucleobase-containing compound catabolic process | 92/2622 | 407/18723 | 1.50e-06 | 6.49e-05 | 92 |
| GO:00467004 | Colorectum | FAP | heterocycle catabolic process | 98/2622 | 445/18723 | 2.36e-06 | 9.21e-05 | 98 |
| GO:00194394 | Colorectum | FAP | aromatic compound catabolic process | 100/2622 | 467/18723 | 6.75e-06 | 2.08e-04 | 100 |
| GO:00009562 | Colorectum | FAP | nuclear-transcribed mRNA catabolic process | 33/2622 | 112/18723 | 1.69e-05 | 4.35e-04 | 33 |
| GO:19023693 | Colorectum | FAP | negative regulation of RNA catabolic process | 25/2622 | 75/18723 | 1.74e-05 | 4.42e-04 | 25 |
| GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
| GO:00105861 | Colorectum | FAP | miRNA metabolic process | 12/2622 | 27/18723 | 1.24e-04 | 2.01e-03 | 12 |
| GO:00434893 | Colorectum | FAP | RNA stabilization | 21/2622 | 65/18723 | 1.33e-04 | 2.13e-03 | 21 |
| GO:00022441 | Colorectum | FAP | hematopoietic progenitor cell differentiation | 29/2622 | 114/18723 | 8.35e-04 | 8.71e-03 | 29 |
| GO:0010587 | Colorectum | FAP | miRNA catabolic process | 6/2622 | 12/18723 | 3.24e-03 | 2.40e-02 | 6 |
| GO:0021543 | Colorectum | FAP | pallium development | 36/2622 | 169/18723 | 6.06e-03 | 3.81e-02 | 36 |
| GO:0071214 | Colorectum | FAP | cellular response to abiotic stimulus | 63/2622 | 331/18723 | 6.38e-03 | 3.99e-02 | 63 |
| GO:0104004 | Colorectum | FAP | cellular response to environmental stimulus | 63/2622 | 331/18723 | 6.38e-03 | 3.99e-02 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |